Table 1.
Summary of key evidence presented for each device
| Device | Phakic state | Mag | Field of view (°) | Study design | Follow-up period (months) | DVA improvement (equivalent LogMAR lines) | NVA improvement (equivalent LogMAR lines unless otherwise stated) | QoL | Endothelial cell loss | Cost effectiveness |
|---|---|---|---|---|---|---|---|---|---|---|
| IOL-VIP | Phakic | 1.3× | 80 | Pilot study [17] 40 eyes of 35 patients | 20 |
+ 5 lines p value not reported |
Not reported | Not reported | 7% | Not reported |
| Case series [19] 13 eyes of 10 patients | 12 |
+ 7 lines (p < 0.001) |
Not reported | Not reported | 11.1% | Not reported | ||||
| LMI | Phakic | 2.5× | 155 | Pilot study [20] 6 eyes | 6 |
+ 3.66 lines (p = 0.14) |
+ 50.83 ETDRS letters (p = 0.14) |
6.66 point improvementa (p = 0.14) | 5.79% | Not reported |
| Orilens | Pseudophakic | 2.5× | 155 |
No published results Awaiting results of RCT |
||||||
| IoL-AMD | Phakic or Pseudophakic | 1.3× | 110 |
Pilot study [22] 18 eyes of 12 patients |
4 |
+ 2 lines p value not reported |
+ 2 lines p value not reported |
Not reported | 18% | Not reported |
| SML | Pseudophakic | 2× | 155 |
Case series [25] 8 eyes of 8 patients |
1 | No changeb |
+ 4.4 lines (Radner chart) compared to + 2.50Add + 2.1 lines (Radner chart) compared to + 6.00Add p values not reported |
Not reported | Not reported | Not reported |
| Not described [26] 8 eyes of 8 patients | 6 | No changeb |
− 1 line (Jaeger chart) compared to + 6.00Add + 5 lines (Jaeger chart) compared to unaided near p values not reported |
Not reported | Not reported | Not reported | ||||
| IMT | Phakic | 2.7× | 20 | Multicentre open label prospective 206 eyes [30] | 12 | + 3.5 lines (p < 0.0001) | + 3.2 lines (p < 0.0001) | + 6 point change in NEIVFQ composite score | 25% | Not reported |
| Multicentre open label prospective 174 eyes [32] | 24 | + 3.7 lines (p < 0.0001) | Not reported | Not reported | 27.4% | Average cost utility ratio $19,001 per QALY | ||||
| Multicentre open label prospective 63 eyes [33] | 60 |
+ 2.4 lines p value not reported |
Not reported | Not reported |
35% in 65 to < 75 year olds 40% in ≥ 75 year olds |
Not reported | ||||
Mag magnification, DVA distance visual acuity, NVA near visual acuity, QoL quality of life
aNon-validated quality of life questionnaire
bSML offers near magnification only